Y Mabs Therapeutics Inc 's ROA from the second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Y Mabs Therapeutics Inc 's ROA in the second quarter of 2025?
Y Mabs Therapeutics Inc recorded a cumulative net loss of $-22 million during 12 months ending in the second quarter of 2025, resulting in a negative return on assets (ROA) of -19.03%.

However, within the Healthcare sector 357 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2025 quarter, so far to 3559, from total ROA ranking in the first quarter of 2025 at 3686.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter
Y / Y Total Assets Change	-20 %	-8.42 %	-67.9 %	-7.29 %	8.79 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-22	-28	-30	-24	-25
Return On Assets (TTM)	-19.03 %	-22.77 %	-23.44 %	-12.56 %	-12.8 %
YMAB's Total Ranking	# 3559	# 3686	# 4298	# 3665	# 3693
Total Assets (TTM) in million	115	113	120	119	144
Seq. Total Assets Change	2.33 %	-6.02 %	0.29 %	-17.05 %	17.14 %
Seq. Net Income Change	-	-	-	-	-

YMAB's 5 Years Annual ROA >> Back to YMAB Management Effectiveness >> Compare YMAB ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 127
Sector	# 358
Overall	# 3511

Return On Assets Statistics
High	Average	Low
-14.28 %	-39.62 %	-74.98 %
(Sep 30 2023)		(Dec 31 2020)

Financial Statements
Y Mabs Therapeutics Inc 's Assets	$ 115 million	YMAB's Balance sheet
Y Mabs Therapeutics Inc 's Income	$ -3 million	Quarterly YMAB's Income Statement
YMAB's Income by Division		See YMAB's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	-67.9 %	163.86 %	-32.89 %	-32.02 %	43.53 %
Total Assets in million	120	373	141	211	310
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-30	-21	-96	-55	-119
Annual Return On Assets	-24.76 %	-5.74 %	-67.56 %	-26.23 %	-38.49 %

YMAB's 5 Years Annual ROA >> Back to YMAB Management Effectiveness >> Compare YMAB ROA to its Competitors

More Return On Assets Ratios
YMAB's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
YMAB's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for YMAB's Competitors
Subscribers only: Roa for Y Mabs Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for YMAB's Customers

You may also want to know
YMAB's Roi	YMAB's Inventory Turnover Ratio	YMAB's Growth Rates	YMAB's Dividend Comparisons
	YMAB's Profitability Ratios	YMAB's Asset Turnover Ratio	YMAB's Dividend Growth
YMAB's Roe	YMAB's Valuation Ratios	YMAB's Financial Strength Ratios	YMAB's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2025, within Healthcare Sector

ROA

Date modified: 2026-08-29T17:41:26+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.